Earlier this quarter, BSEM management preannounced preliminary results that showed record 4Q net revenues. If this is confirmed in the soon-to-be-released 2024 fiscal results, Zack's could be ready to lift its current price target of $32.50 to even higher levels!
There's a part of the medical arena that barely gets discussion and that's wound care. Wound care is crucial for preventing infections, promoting faster healing, and minimizing complications, ultimately improving overall health and well-being.
How important is wound care? Enough that Zack's Small Cap Research has seen the potential in one undervalued company in the space. BioStem Technologies (OTC: BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain ® processing method. BioREtain ® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure.
Most recently Zack's gave BSEM a price target of $32.50 and believes the company provides a vital service to the human population and provides economic value to shareholders.
At the end of last year BSEM signed a Letter of Intent (LOI) to acquire commercial-stage products and development technologies from ProgenaCare. a pioneering medical device company leveraging cutting-edge advances in biomaterials to provide effective, affordable advanced wound care solutions.
ProgenaCare's flagship product, ProgenaMatrix, is the first and only commercially available human keratin matrix for wound care. This advanced wound care solution is FDA 510(k) cleared for a broad range of indications, including venous stasis ulcers, diabetic foot ulcers, surgical wounds, and partial-thickness burns.
The addition of ProgenaCare's 510(k) cleared products will enhance BSEM's position in the hospital-based segments of the market, while ProgenaCare's proprietary technology platforms and product pipeline offer significant opportunities for the company to help drive future growth.
Additionally, the company continues the process of uplisting its stock to the NASDAQ stock exchange, which should improve access and liquidity for investors in BSEM
See why now is an ideal time to have BSEM on your watch list as the company gears up to release its fiscal 2024 results.
This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc. has received a fixed fee of $6000 from Sideways Frequency for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between March 27, 2025 and April 2, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
No comments:
Post a Comment